The peritoneal carcinomatosis of gastric cancer is a current therapeutic difficulty and the related clinical data are still limited so far. In this study, we evaluated efficacy and safety of the recombinant human endostatin (Endostar) characterized by broad-spectrum anti-angiogenesis combined with chemotherapy on gastric cancer peritoneal carcinomatosis.
From Jan. 2014 to Dec. 2016, 33 advanced stage gastric cancer patients associated with peritoneal carcinomatosis were enrolled. Their pathological information, imaging as well as therapy information were retrospectively analyzed. Twenty-one patients only received systemic chemotherapy as control group, and twelve patients received Endostar combined with chemotherapy as combination therapy group. All the 33 patients were evaluated on phase-efficacy and followed-up to record survival time. The tumor time to progression (TTP), overall survival (OS), Objective Response Rate (ORR), disease control rate (DCR) and therapy-related adverse reactions were evaluated to confirm effect of Endostar therapy.
All the patients were evaluable. The evaluation on efficacy indicated that Endostar combined with chemotherapy increased ORR (41.6% vs. 23.81%) and DCR (83.3% vs. 61.91%) compared with control group, although there was no statistical difference between them. The survival analysis indicated that Endostar combined with chemotherapy effectively extended time to disease progression (4.60 ± 0.32 months vs. 3.50 ± 0.34 months, P = 0.03), and the median OS (15.80 ± 3.4 months vs. 9.80 ± 0.7 months, P = 0.01) compared with single chemotherapy. Furthermore, the evaluation on adverse reactions indicated that combination therapy did not have more adverse reactions.
The recombinant endostatin with broad-spectrum anti-angiogenesis could effectively control the development of peritoneal carcinomatosis disease and extend survival with high safety and tolerance. However, further prospective study needs to be performed to confirm the clinical application value.
Clinical trial identification
This retrospective study was approved by hospital ethical committee and all informed consent were obtained.
Legal entity responsible for the study
This study was approved by hospital ethical committee and all informed consent were obtained.
All authors have declared no conflicts of interest.